The company's cell therapies use the innate antitumor biology and safety features of NK cells. They target cancer through the use of chimeric antigen receptors (CARs) or antibody-dependent cellular cytotoxicity (ADCC) enhancement through therapeutic antibody or innate cell engager combination therapy.

The company's pipeline includes the following:

• AB-101, an ADCC enhancer NK cell therapy for use in combination with monoclonal antibodies or innate cell engagers
• AB-201, a novel human epidermal growth factor receptor 2 (HER2)-specific CAR-NK cell therapy for treating HER2+ solid tumors
• AB-202, a CD19-specific CAR-NK cell therapy for treating B-cell malignancies

The NK cell platform incorporates cell expansion, activation, and engineering technology developed by corporate partner GC LabCell, a member of the GC family of companies.

Artiva's manufacturing platform supports large-scale production and cryopreservation of off-the-shelf allogeneic NK cell therapies and proprietary CAR-NK and NK-specific gene-editing technologies to augment therapeutic activity, Artiva said.

The series B financing round was led by Venrock Healthcare Capital Partners.